Precision Neuroscience
Precision Neuroscience Corp
Brain-computer interface technology company developing minimally invasive, removable, high-bandwidth treatments.
precisionneuro.io · New York, NY
Funding event
The round itself, as filedStage · pressSeries D
Sold of offered$250M of Indefinite
Filed2026-09-28
Days since filing5
- Exemption claimed
- Rule 506(b)
- First-ever Form D
- No
- Date of first sale
- 2026-09-11
Investors · press-matched
Pershing Square Inc.Ackman Oxman InstituteDuquesne Family OfficeB CapitalARK InvestInvusMubadala CapitalMirae Asset CapitalKorea Investment PartnersHitachi VenturesJSL Health CapitalPress release
Form D does not name investors; these come from the matched release, as a fact with a link.
Officers on the filing
Names and roles as filed; addresses are never stored- Michael MagerExecutive Officer · Director
- Konstantinos AlatarisExecutive Officer · Director
- Craig MermelExecutive Officer · Director
- Benjamin RapoportExecutive Officer · Director
- Ravi MehtaDirector
- Howard MorganDirector
- Michael KaswanExecutive Officer
- Michael GollerDirector
- Stephen BiggarDirector
Health flags
Three flags, each with the raw inputs behind it · as of 2026-10-03UndersubscribedNot flagged—0.7 months since first sale
Prior raiseNot flaggedPrior raise not known—
AmendedNot flaggedNo amendmentNo D/A on file
Open roles
On the employer's own careers page · checked 2026-10-010
Pre-posting windowNot enough dataShown once this sector and stage have 20 observed lags from filing to first posting.
No open roles foundWe read careers pages daily.
Also raised in Health & bio
Same sector, 28 days to 2026-10-04Altay TherapeuticsSeries A · $15.7M of $45.1M · San Carlos, CAQuietCarebilitySeries A · $8.8M of $8.8M · Richardson, TXQuiet
75 rounds in Health & bio in the 28 days to 2026-10-02, against 71 in the 28 days before.